Amicus shares surge as Sanofi struggles to raise a cheer for mixed pivotal data for a PhIII contender — and analysts blow a raspberry

Sanofi took extra time on Tuesday to offer an upbeat assessment of its top-line results for a pivotal study of a new ERT for late-onset Pompe disease. But with Amicus breathing down its neck with a Phase III rival of its own, the pharma giant was treated to some unwelcome reviews from a slate of analysts covering the matchup.